A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis
Purpose: Pancreatic cancer is the fourth leading cause of cancer death in the United States, and new drugs to treat the disease are needed. Pancreatic cancer cells are highly metastatic and exhibit resistance to apoptosis. Small molecules that can restore sensitivity to apoptosis or reduce metastasis would have therapeutic potential against this disease. Manzamine A is an alkaloid isolated from marine sponges that was suspected to have inhibitory activity against the mitogen activated kinase kinase (MEK). Because of this, the effects of Manzamine A were studied in pancreatic cancer cells. Methods: AsPC-1 cells were treated for 48 h in the presence of various concentrations of Manzamine A and their phenotype, cytotoxicity, cell invasion and susceptibility to apoptosis were observed. Results: Manzamine A decreased single cell formation, abrogated cell migration and restored the susceptibility of the cells to TRAIL-induced apoptosis in AsPC-1 cells. Its mechanism of action remains unknown, as manzamine A does not inhibit MEK. Conclusions: Manzamine A appears to have a formerly unrecognized activity in blocking tumor cell invasion as well as in restoring cancer cell susceptibility to apoptosis in vitro and therefore has the potential to be used as an adjuvant to existing cancer therapies.
KeywordsNatural products Pancreatic cancer Drug discovery Mechanism of action
Funding for this project was provided by NIH/NCI 1R01CA093455-01A1, the State of Florida Center of Excellence in Biomedical & Marine Biotechnology (COE-HRE07), and the Health Resources & Services Administration Center for Sustainable Use of Marine Resources (4C76HF00231-01-04).
- 1.All About Pancreatic Cancer. American Cancer Society. http://www.cancer.org/docroot/CRI/CRI_2x.asp?sitearea=&dt=34 (accessed 10/01/09).
- 6.Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M (2003) Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 201:107–116PubMedCrossRefGoogle Scholar
- 11.Yousaf M, Hammond NL, Peng J, Wahyuono S, McIntosh KA, Charman WN, Mayer AM, Hamann MT (2004) New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. J Med Chem 47:3512–3517PubMedCrossRefGoogle Scholar
- 12.Peng J, Hu JF, Kazi AB, Li Z, Avery M, Peraud O, Hill RT, Franzblau SG, Zhang F, Schinazi RF, Wirtz SS, Tharnish P, Kelly M, Wahyuono S, Hamann MT (2003) Manadomanzamines A and B: a novel alkaloid ring system with potent activity against mycobacteria and HIV-1. J Am Chem Soc 125:13382–13386PubMedCrossRefGoogle Scholar
- 17.Hamann M, Alonso D, Martin-Aparicio E, Fuertes A, Perez-Puerto MJ, Castro A, Morales S, Navarro ML, Del Monte-Millan M, Medina M, Pennaka H, Balaiah A, Peng J, Cook J, Wahyuono S, Martinez A (2007) Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer’s disease. J Nat Prod 70:1397–1405PubMedCrossRefGoogle Scholar
- 21.Hill RT, Hamann M, Peraud O, Kasanah N (2003) Manzamine-producing Actinomycetes. Patent Application Number PCT/US2003/024238, USAGoogle Scholar